×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TECH – bio-techne corp (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TECH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/4
06:30 am
tech
3 Reasons to Avoid TECH and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Avoid TECH and 1 Stock to Buy Instead [Yahoo! Finance]
3/3
01:47 pm
tech
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/3
05:20 am
tech
Middle East DNA Synthesis Market Research Report 2026: $7.6 Bn Industry Trends and Forecasts to 2035 - Precision Medicine, Molecular Diagnostics and Biopharma R&D Investments Accelerate Demand [Yahoo! Finance]
Low
Report
Middle East DNA Synthesis Market Research Report 2026: $7.6 Bn Industry Trends and Forecasts to 2035 - Precision Medicine, Molecular Diagnostics and Biopharma R&D Investments Accelerate Demand [Yahoo! Finance]
2/28
03:42 pm
tech
Will Ella CE-IVD Approval in EU Clinical Labs Change Bio-Techne's (TECH) Diagnostic Platform Narrative? [Yahoo! Finance]
Low
Report
Will Ella CE-IVD Approval in EU Clinical Labs Change Bio-Techne's (TECH) Diagnostic Platform Narrative? [Yahoo! Finance]
2/24
02:35 pm
tech
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections [Yahoo! Finance]
Low
Report
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections [Yahoo! Finance]
2/24
07:21 am
tech
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/24
07:00 am
tech
Bio-Techne to Present at Upcoming Investor Conferences
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences
2/21
06:30 pm
tech
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Medium
Report
Bio-Techne (NASDAQ:TECH) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
06:48 pm
tech
Form 3 BIO-TECHNE Corp For: Mar 01 Filed by: Crouse Steven C.
Low
Report
Form 3 BIO-TECHNE Corp For: Mar 01 Filed by: Crouse Steven C.
3/4
06:48 pm
tech
Form 4 BIO-TECHNE Corp For: Mar 02 Filed by: Crouse Steven C.
Low
Report
Form 4 BIO-TECHNE Corp For: Mar 02 Filed by: Crouse Steven C.
2/19
04:58 pm
tech
Form 4 BIO-TECHNE Corp For: Feb 17 Filed by: Herr Amy E.
Low
Report
Form 4 BIO-TECHNE Corp For: Feb 17 Filed by: Herr Amy E.
2/17
04:19 pm
tech
Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.
Low
Report
Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.
2/11
04:30 pm
tech
Form 8-K BIO-TECHNE Corp For: Feb 09
Medium
Report
Form 8-K BIO-TECHNE Corp For: Feb 09
2/5
06:30 pm
tech
Form 4 BIO-TECHNE Corp For: Feb 03 Filed by: Herr Amy E.
Medium
Report
Form 4 BIO-TECHNE Corp For: Feb 03 Filed by: Herr Amy E.
2/4
04:31 pm
tech
Form 10-Q BIO-TECHNE Corp For: Dec 31
Medium
Report
Form 10-Q BIO-TECHNE Corp For: Dec 31
2/4
06:30 am
tech
Form 8-K BIO-TECHNE Corp For: Feb 04
Medium
Report
Form 8-K BIO-TECHNE Corp For: Feb 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
12.5%
4/30 Q3/2020 3/31/2020 EPS 1.390 ZacksConsensus 1.010 ActVsEst 0.380 - Beat 6.1%
5/1 BIO-TECHNE Corp (NASDAQ: TECH) had its price target raised by analysts at Wells Fargo & Co from $190.00 to $220.00. They now have an "equal weight" rating on the stock. 5.7%
4/16 Bio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess™ 5.2%
11/14 BIO-TECHNE Corp (NASDAQ: TECH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 4.4%
3/30 Extracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets 4.0%
8/13 Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay 3.6%
4/25 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.5%
4/1 Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member 2.9%
10/28 Bio-Techne Announces Investment For New GMP Manufacturing Facility 2.9%
4/30 Q3/2020 3/31/2020 EPS 1.390 ZacksConsensus 1.010 ActVsEst 0.380 - Beat 6.1%
5/1 BIO-TECHNE Corp (NASDAQ: TECH) had its price target raised by analysts at Wells Fargo & Co from $190.00 to $220.00. They now have an "equal weight" rating on the stock. 5.7%
4/16 Bio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess™ 5.2%
11/14 BIO-TECHNE Corp (NASDAQ: TECH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 4.4%
3/30 Extracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets 4.0%
8/13 Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay 3.6%
4/25 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.5%
4/1 Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member 2.9%
10/28 Bio-Techne Announces Investment For New GMP Manufacturing Facility 2.9%
TOP News Decliners
3/20
BIO-TECHNE Corp (NASDAQ: TECH) had its price target lowered by analysts at Citigroup Inc from $225.00 to $175.00. They now have a "neutral" rating on the stock.
-4.6%
4/21 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.4%
5/7 Form 10-Q BIO-TECHNE Corp For: Mar 31 -2.9%
3/6 Form 4 BIO-TECHNE Corp For: Mar 04 Filed by: Eansor Norman David -2.9%
3/18 Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration -2.8%
8/6 Q4/2019 6/30/2019 EPS 1.250 ZacksConsensus 1.170 ActVsEst 0.080 - Beat -2.7%
2/27 Bio-Techne To Present At The Barclays Global Healthcare Conference -2.4%
10/8 Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results -2.3%
2/24 Bio-Techne To Present At The Cowen 40th Annual Health Care Conference -2.2%
7/10 Form 4 BIO-TECHNE Corp For: Jul 08 Filed by: Kummeth Charles R. -2.1%
4/21 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.4%
5/7 Form 10-Q BIO-TECHNE Corp For: Mar 31 -2.9%
3/6 Form 4 BIO-TECHNE Corp For: Mar 04 Filed by: Eansor Norman David -2.9%
3/18 Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration -2.8%
8/6 Q4/2019 6/30/2019 EPS 1.250 ZacksConsensus 1.170 ActVsEst 0.080 - Beat -2.7%
2/27 Bio-Techne To Present At The Barclays Global Healthcare Conference -2.4%
10/8 Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results -2.3%
2/24 Bio-Techne To Present At The Cowen 40th Annual Health Care Conference -2.2%
7/10 Form 4 BIO-TECHNE Corp For: Jul 08 Filed by: Kummeth Charles R. -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: